Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

United States Vaccine Market By Type (Influenza, Retrovirus, Hepatitis, Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV), Products and Pipeline, Companies

Published by Renub Research Product code 973146
Published Content info 241 Pages
Delivery time: 1-2 business days
Price
Back to Top
United States Vaccine Market By Type (Influenza, Retrovirus, Hepatitis, Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV), Products and Pipeline, Companies
Published: November 1, 2020 Content info: 241 Pages
Description

The average human life span has grown significantly primarily due to vaccination. Vaccines have transformed public health throughout the world, especially for children. In the United States, among the various diseases like Influenza, Rotavirus, Hepatitis (Hepatitis A and Hepatitis B), Polio, DTap, HIB, Pneumococcal conjugate, Varicella, MMR and HPV, influenza is the most common viral infection. Quadrivalent is the most common flu vaccines in the United States, which was licensed in the year 2012. According to Renub Research, United States Vaccine Market is poised to reach US$ 11.4 Billion by 2026.

Although influenza can catch anyone anytime in the year, usually it spreads between May to October. So in August National Immunization Awareness day is being celebrated to increase the awareness and the importance of vaccination in the nation. These immunizations awareness and government initiatives have helped to prevent 2-3 million deaths annually according to the World Health Organisation. There is no other health intervention as simple, powerful, and cost-effective as a 'vaccine'.

In this report, we have studied key players like GlaxoSmithKline, plc, Merck & Co, Sanofi Pasteur and Pfizer, Inc their trends and implication which has given these companies to view in a strategic way. Apart from that, companies are evaluated on parameters like:

  • Overviews
  • Recent Developments
  • Revenues
  • Vaccinations Pipeline & Clinical Trials

Renub Research report titled "United States Vaccine Market By Vaccine Type (Vaccines Market, Immunized Population and Administered Doses), Influenza (Trivalent Flu Vaccine and Quadrivalent Flu Vaccine), Retrovirus, Hepatitis (Hepatitis A and B), Polio, DTap, HIB, Pneumococcal Conjugate, Varicella, MMR and HPV) Vaccines Products and Pipeline, Company Analysis (GlaxoSmithKline, plc, Merck & Co, Sanofi Pasteur and Pfizer, Inc.)" provides an all-encompassing analysis on the United States Vaccine Industry.

All the 10 Vaccines have been studied from 3 points

  • Vaccines Market
  • Immunized Population (Infants)
  • Doses of Vaccines Administered

Vaccine Type - The Report Covers the Market, Immunized Population and Administered Doses of all the 10 diseases

  • 1. Influenza Vaccines
  • 2. Retrovirus
  • 3. Hepatitis A & B
  • 4. Polio
  • 5. DTaP
  • 6. HIB
  • 7. Pneumococcal conjugate
  • 8. Varicella
  • 9. MMR
  • 10. HPV

All the company analysis has been covered from 4 Viewpoints

  • Overview
  • Recent Developments
  • Revenue Analysis
  • Vaccinations Pipeline & Clinical Trials

Company Analysis

  • GlaxoSmithKline, plc
  • Merck & Co
  • Sanofi Pasteur
  • Pfizer, Inc.
Table of Contents

Table of Contents

1. Introduction

2. Research & Methodology

3. Executive Summary

4. Market Dynamics

  • 4.1 Growth Drivers
  • 4.2 Challenges

5. United States Vaccine Analysis

  • 5.1 Vaccine Market
  • 5.2 Immunized Population
  • 5.3 Doses of Vaccines Administered

6. Share Analysis

  • 6.1 Market Share by Vaccine Type
  • 6.2 Volume Share by Vaccine Type

7. Disease wise - Vaccines Market& Volume and Forecast

  • 7.1 Influenza Vaccines Market & Types
    • 7.1.1 Trivalent Flu Vaccine
    • 7.1.2 Quadrivalent Flu Vaccine
    • 7.1.3 Administered Doses
  • 7.2 Rotavirus
    • 7.2.1 Vaccines Market
    • 7.2.2 Immunized Population (Infants)
    • 7.2.3 Administered Doses
  • 7.3 Hepatitis B
    • 7.3.1 Vaccines Market
    • 7.3.2 Immunized Population (Infants)
    • 7.3.3 Administered Doses
    • 7.3.4 Hepatitis A
  • 7.4 Polio
    • 7.4.1 Vaccines Market
    • 7.4.2 Immunized Population (Infants + Children)
    • 7.4.3 Administered Doses
  • 7.5 DTaP
    • 7.5.1 Vaccines Market
    • 7.5.2 Immunized Population
    • 7.5.3 Administered Doses
  • 7.6 HIB
    • 7.6.1 Vaccines Market
    • 7.6.2 Immunized Population (Infants)
    • 7.6.3 Administered Doses
  • 7.7 Pneumococcal conjugate
    • 7.7.1 Vaccines Market
    • 7.7.2 Immunized Population (Infants)
    • 7.7.3 Administered Doses
  • 7.8 Varicella
    • 7.8.1 Vaccines Market
    • 7.8.2 Immunized Population (Infants + 4-6 years old)
    • 7.8.3 Administered Doses
  • 7.9 MMR
    • 7.9.1 Vaccines Market
    • 7.9.2 Immunized Population (Infants + 4-6 years old)
    • 7.9.3 Administered Doses
  • 7.10 HPV
    • 7.10.1 Vaccines Market
    • 7.10.2 Immunized Population (Immunized Girl)
    • 7.10.3 Administered Doses

8. Vaccines - Products and Pipeline

  • 8.1 GlaxoSmithKline, plc
  • 8.2 Merck & Co
  • 8.3 Sanofi Pasteur
  • 8.4 Pfizer, Inc.

9. Top Mergers and Acquisitions in the Vaccine Industry

10. Key Players

  • 10.1 GlaxoSmithKline, plc.'s Vaccines Sales
  • 10.2 Merck & Co. Vaccines Sales
  • 10.3 Sanofi Pasteur's Vaccines Sales
  • 10.4 Pfizer, Inc.'s Vaccines Sales

List of Figures

  • Figure-01: United States - Vaccine Market (Million US$), 2016 - 2019
  • Figure-02: United States - Forecast For Vaccine Market (Million US$), 2020 - 2026
  • Figure-03: United States - Immunized Population (Million), 2016 - 2019
  • Figure-04: United States - Vaccine Market (Million US$), 2016 - 2019
  • Figure-05: United States - Forecast For Vaccine Market (Million US$), 2020 - 2026
  • Figure-06: United States - Immunized Population (Million), 2016 - 2019
  • Figure-07: United States - Forecast for Immunized Population (Million) - 2020-2026
  • Figure-08: United States - Doses of Vaccines Administered (Million), 2016 - 2019
  • Figure-09: United States - Forecast For Doses of Vaccines Administered (Million), 2020 - 2026
  • Figure-10: United States - Influenza Vaccines Market (Million US$), 2015 - 2019
  • Figure-11: United States - Forecast For Influenza Vaccines Market (Million US$), 2020 - 2026
  • Figure-12: United States - Trivalent flu Vaccines (Million US$), 2014 - 2019
  • Figure-13: United States - Forecast For Trivalent flu Vaccine (Million US$), 2020 - 2026
  • Figure-14: United States - Quadrivalent flu Vaccine (Million US$), 2017- 2019
  • Figure-15: United States - Forecast For Quadrivalent flu Vaccine (Million US$), 2020 - 2026
  • Figure-16: United States - Administered Doses (Million), 2017 - 2019
  • Figure-17: United States - Forecast For Administered Doses (Million), 2020 - 2026
  • Figure-18: United States - Rotavirus Vaccines Market (Million US$), 2015 - 2019
  • Figure-19: United States - Forecast For Rotavirus Vaccines Market (Million Pound), 2020 - 2026
  • Figure-20: United States - Rotavirus Immunized Infants (Million), 2015 - 2019
  • Figure-21: United States - Forecast For Rotavirus Immunized Infants (Million), 2020 - 2026
  • Figure-22: United States - Rotavirus Administered Doses (Million), 2015 - 2019
  • Figure-23: United States - Forecast For Rotavirus Administered Doses (Million), 2020 - 2026
  • Figure-24: United States - Hepatitis B Vaccines Market (Million US$), 2015 - 2019
  • Figure-25: United States - Forecast For Hepatitis B Vaccines Market (Million US$), 2020 - 2026
  • Figure-26: United States - Hepatitis B Immunized Population (Million), 2015 - 2019
  • Figure-27: United States - Forecast For Hepatitis B Immunized Population (Million), 2020 - 2026
  • Figure-28: United States - Hepatitis B Administered Doses (Million), 2015 - 2019
  • Figure-29: United States - Forecast For Hepatitis B Administered Doses (Million), 2020 - 2026
  • Figure-30: United States - Hepatitis A Vaccines Market (Million US$), 2015 - 2019
  • Figure-31: United States - Forecast For Hepatitis A Vaccines Market (Million US$), 2020 - 2026
  • Figure-32: United States - Hepatitis A Immunized Infants (Million), 2015 - 2019
  • Figure-33: United States - Forecast For Hepatitis A Immunized Infants (Million), 2020 - 2026
  • Figure-34: United States - Hepatitis B Administered Doses (Million), 2015 - 2019
  • Figure-35: United States - Forecast For Hepatitis B Administered Doses (Million), 2020 - 2026
  • Figure-36: United States - Polio Vaccine Market (Million US$), 2015 - 2019
  • Figure-37: United States - Forecast For Polio Vaccine Market (Million US$), 2020 - 2026
  • Figure-38: United States - Polio Immunized Infants (Million), 2015 - 2019
  • Figure-39: United States - Forecast For Polio Immunized Infants (Million), 2020 - 2026
  • Figure-40: United States - Polio Administered Doses (Million), 2015 - 2019
  • Figure-41: United States - Forecast for Polio Administered Doses (Million), 2020 - 2026
  • Figure-42: United States - DTaP Vaccines Market (Million US$), 2015 - 2019
  • Figure-43: United States - Forecast For DTaP Vaccines Market (Million US$), 2020 - 2026
  • Figure-44: United States - DTaP Immunized Population (Million), 2015 - 2019
  • Figure-45: United States - Forecast For DTaP Immunized Population (Million), 2020 - 2026
  • Figure-46: United States - DTaP Administered Doses (Million), 2015 - 2019
  • Figure-47: United States - Forecast For DTaP Administered Doses (Million), 2020 - 2026
  • Figure-48: United States - HIB Vaccine Market (Million US$), 2015 - 2019
  • Figure-49: United States - Forecast For - HIB Vaccine Market (Million US$), 2020 - 2026
  • Figure-50: United States - HIB Immunized Infants (Million), 2015 - 2019
  • Figure-51: United States - Forecast For HIB Immunized Infants (Million ), 2020 - 2026
  • Figure-52: United States - HIB Administered Doses (Million), 2015 - 2019
  • Figure-53: United States - Forecast For HIB Administered Doses (Million), , 2020 - 2026
  • Figure-54: United States - Pneumococcal conjugate Vaccines Market (Million US$), 2015 - 2019
  • Figure-55: United States - Pneumococcal conjugate Vaccines Market (Million US$), 2020 - 2026
  • Figure-56: United States - Pneumococcal conjugate Immunized Population (Million), 2015 - 2019
  • Figure-57: United States - Forecast For Pneumococcal conjugate Immunized Population (Million), 2020 - 2026
  • Figure-58: United States - Pneumococcal conjugate Administered Doses (Million), 2015 - 2019
  • Figure-59: United States - Forecast For Pneumococcal conjugate Administered Doses (Million), 2020 - 2026
  • Figure-60: United States - Varicella Vaccines Market (Million US$), 2015 - 2019
  • Figure-61: United States - Forecast For Varicella Vaccines Market (Million US$), 2020 - 2026
  • Figure-62: United States - Varicella Immunized Infants (Million), 2015 - 2019
  • Figure-63: United States - Forecast For Varicella Immunized Infants (Million), 2020 - 2026
  • Figure-64: United States - Varicella Administered Doses (Million), 2015 - 2019
  • Figure-65: United States - Forecast For Varicella Administered Doses (Million), 2020 - 2026
  • Figure-66: United States - MMR Vaccine Market (Million US$), 2015 - 2019
  • Figure-67: United States - Forecast For MMR Vaccine Market (Million US$), 2020 - 2026
  • Figure-68: United States - MMR Immunized Population (Million), 2015 - 2019
  • Figure-69: United States - Forecast For MMR Immunized Population (Million ), 2020 - 2026
  • Figure-70: United States - Administered Doses (Million), 2015 - 2019
  • Figure-71: United States - Forecast For Administered Doses (Million), 2020 - 2026
  • Figure-72: United States - HPV Vaccine Market (Million US$), 2015 - 2019
  • Figure-73: United States - Forecast For HPV Vaccine Market (Million), 2020 - 2026
  • Figure-74: United States - HPV Immunized Girl (Million), 2015 - 2019
  • Figure-75: United States - Forecast For HPV Immunized Girl (Million), 2020 - 2026
  • Figure-76: United States - HPV Administered Doses (Million), 2015 - 2019
  • Figure-77: United States - Forecast For HPV Administered Doses (Million ), 2020 - 2026
  • Figure-78: Global - GlaxoSmithKline, plc.'s Vaccine Revenue (Million US$), 2015 - 2019
  • Figure-79: Global - Forecast For GlaxoSmithKline plc.'s Vaccine Revenue (Million US$), 2020 - 2026
  • Figure-80: Global - Merck & Co. Vaccine Revenue (Million US$), 2015 - 2019
  • Figure-81: Global - Forecast For Merck & Co. Vaccine Revenue (Million US$), 2020 - 2026
  • Figure-82: Global - Sanofi Pasteur's Vaccines Revenue (Million US$), 2015 - 2019
  • Figure-83: Global - Forecast For Sanofi Pasteur's Vaccines Revenue ( Million US$) 2020 - 2026
  • Figure-84: Global - Pfizer, Inc.'s Vaccine Revenue (Million US$), 2015 - 2020
  • Figure-85: Global - Forecast For Pfizer, Inc.'s Vaccine Revenue (Million US$), 2020 - 2026

List of Tables:

  • Table-01: United States - Market Share by Vaccine Type (Percentage), 2017 - 2020
  • Table-02: United States - Forecast For Market Share by Vaccine Type (Percentage), 2020 - 2026
  • Table-03: United States - Volume Share by Vaccine Type (Percentage), 2017 - 2020
  • Table-04: United States - Forecast For Volume Share by Vaccine Type (Percentage), 2020 - 2026
  • Table-05: GlaxoSmithKline, plc. Products & Pipelines
  • Table-06: Sanofi Pasteur Products & Pipelines
  • Table-07: Pfizer Products & Pipelines
Back to Top